Treatment of cardiac sarcoidosis with interleukin-1 receptor-FC fusion protein

The use of interleukin-1 receptor-Fc fusion protein effectively reduces inflammation markers and improves quality of life in patients with cardiac sarcoidosis, addressing the limitations of current treatments by offering a safer alternative to immunosuppressive therapies.

WO2026128826A1PCT designated stage Publication Date: 2026-06-18REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
REGENERON PHARMACEUTICALS INC
Filing Date
2025-12-12
Publication Date
2026-06-18

Smart Images

  • Figure IMGF000088_0001
    Figure IMGF000088_0001
  • Figure IMGF000011_0001
    Figure IMGF000011_0001
  • Figure IMGF000090_0001
    Figure IMGF000090_0001
Patent Text Reader

Abstract

Disclosed herein is a method of treating cardiac sarcoidosis in a subject in need thereof, comprising administering to the subject an interleukin-1 receptor-Fc fusion protein at a therapeutically effective dose.
Need to check novelty before this filing date? Find Prior Art